Tesamorelin
Stabilized GHRH analog — the only FDA-approved growth-hormone-releasing peptide
Select pack size
Buy now
Card, Apple Pay, SEPA bank transfer or crypto · 3D-Secure
Lot-specific COA
HPLC >99% — Janoshik analysis on request
Plain, discreet packaging
No contents named on the outer label
Dispatched in 1 business day
Tracked worldwide shipping
About Tesamorelin
Tesamorelin is a stabilized 44-amino-acid GHRH analog that prompts the pituitary to release growth hormone in its natural pulsatile rhythm. In Phase 3 trials (NEJM 2007) it cut visceral fat by ~15% over 26 weeks, and it is the only GHRH peptide with FDA approval (Egrifta). Supplied as lyophilized powder; reconstitute a 10 mg vial in 1 mL for 10 mg/mL. Research use only.
Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH 1-44) carrying an N-terminal trans-3-hexenoyl modification that resists rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). It was developed by Theratechnologies and is the only GHRH analog to have received FDA approval (marketed as Egrifta, approved 2010 for HIV-associated lipodystrophy). Unlike administering recombinant growth hormone directly, tesamorelin acts upstream on the pituitary somatotrophs, stimulating the gland to secrete its own growth hormone in the natural pulsatile rhythm that the body regulates through endogenous somatostatin feedback. This preservation of physiological pulsatility is the central reason researchers distinguish GHRH analogs from exogenous GH. In the pivotal Phase 3 registration program (Falutz et al., New England Journal of Medicine, 2007; n=412), tesamorelin reduced visceral adipose tissue (VAT) by approximately 15% over 26 weeks while increasing IGF-1 and improving the triglyceride profile, without a clinically meaningful worsening of fasting glucose. A confirmatory analysis by Stanley et al. (JAMA, 2014) extended the visceral-fat and liver-fat findings, reporting a reduction in hepatic fat fraction. The effect on visceral fat reversed when treatment was discontinued, underscoring that the response is dependent on continued GHRH signaling. Tesamorelin is supplied as a lyophilized powder and reconstituted with bacteriostatic water prior to use. It is frequently studied alongside other GH secretagogues such as CJC-1295 (a longer-acting GHRH analog) and ipamorelin (a selective ghrelin-receptor / GH-secretagogue-receptor agonist) to compare pulsatile-release profiles.
Specifications
- The only GHRH analog with FDA approval (Egrifta, 2010) — most-validated peptide in the GH-secretagogue class
- Reduced visceral adipose tissue by ~15% over 26 weeks in a Phase 3 trial (Falutz et al., NEJM 2007, n=412)
- Significant reduction in liver-fat fraction confirmed by JAMA 2014 (Stanley et al.)
- N-terminal trans-3-hexenoyl modification resists DPP-4 degradation, extending half-life over native GHRH
- Acts upstream on the pituitary — preserves the natural pulsatile rhythm of GH secretion
- Raises IGF-1 and improves the triglyceride profile without clinically meaningful glucose worsening
- Effect on visceral fat reverses on discontinuation — response depends on continued GHRH signaling
- Frequently compared with CJC-1295 (longer-acting GHRH) and ipamorelin (selective GHS-R agonist) in research
Research context
The registration trial is Falutz et al., "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV", New England Journal of Medicine, Volume 357, Pages 2359–2370 (2007), DOI: 10.1056/NEJMoa072375. This randomized, double-blind, placebo-controlled study enrolled 412 patients and documented a ~15% reduction in visceral adipose tissue over 26 weeks. The liver-fat findings are reported in Stanley et al., "Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation", JAMA, Volume 312, Pages 380–389 (2014), DOI: 10.1001/jama.2014.8334, which showed a significant decrease in hepatic fat fraction measured by proton magnetic resonance spectroscopy. The molecule maintains pulsatile GH release because the pituitary remains under negative feedback from somatostatin and IGF-1, a mechanism reviewed in Sigalos & Pastuszak (Sexual Medicine Reviews, 2018) on growth-hormone secretagogues. Tesamorelin received FDA approval in 2010 (Egrifta) for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It is not approved for, and was not studied for, general weight loss, anti-aging or athletic performance — those remain outside the clinical evidence base.
Storage & handling
Temperature
-20°C (lyophilized) / 2–8°C (reconstituted)
Conditions
Protect from direct light and moisture
Shelf life
18 months (lyophilized, sealed vial)
Reconstitution of Tesamorelin
Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Volume
1–2 mL
Concentration
10 mg/mL at 1 mL, 5 mg/mL at 2 mL (10 mg vial)
Step-by-step
- 1Allow the vial and bacteriostatic water to reach room temperature (15–20 minutes).
- 2Use an alcohol swab to disinfect the rubber stoppers of both the peptide vial and the water vial.
- 3Draw the desired amount of bacteriostatic water (1–2 mL) using a sterile 1-mL insulin syringe.
- 4Place the needle against the side of the vial and let the water run slowly down the inner wall — never spray directly onto the lyophilized powder.
- 5Gently swirl the vial or roll it between your palms until the powder is fully dissolved. Never shake.
- 6Visually inspect the clear solution for particulates. Do not use if cloudy or if visible particles are present.
- 7Store reconstituted Tesamorelin immediately at 2–8°C and use within 7–14 days — GHRH analogs are less stable in solution.
- 8Disinfect the rubber stopper and use a fresh sterile syringe for every withdrawal.
Frequently asked questions
What is Tesamorelin and how does it work?
Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH). It acts on the pituitary gland to increase the body’s own growth-hormone secretion in its natural pulsatile rhythm, rather than supplying growth hormone directly. It is the only GHRH analog approved by the FDA (as Egrifta).
How is Tesamorelin reconstituted?
The lyophilized powder is reconstituted with bacteriostatic water added slowly down the inner wall of the vial, then swirled gently — never shaken. A 10 mg vial in 1 mL yields 10 mg/mL; in 2 mL it yields 5 mg/mL.
How is Tesamorelin stored?
Store the sealed lyophilized vial at -20°C for long-term stability. After reconstitution, keep refrigerated at 2–8°C, protect from light, and use within 1–2 weeks, as GHRH analogs are less stable in solution.
What is the purity of this Tesamorelin?
Our Tesamorelin is supplied at >99% purity (HPLC-verified), with a batch Certificate of Analysis available on request from a named laboratory. Mass spectrometry should match the expected molecular mass for the 44-amino-acid analog.
How does Tesamorelin differ from CJC-1295 and ipamorelin?
Tesamorelin and CJC-1295 are both GHRH analogs that act on the pituitary; tesamorelin is the FDA-validated one, while CJC-1295 is longer-acting. Ipamorelin works through a different receptor (the ghrelin / GH-secretagogue receptor). They are often studied in parallel to compare pulsatile GH-release profiles.
Order Tesamorelin
From €72 · Purity >99%· Dispatched within 1 business day
Research reference
Read the Tesamorelin research guide
Dosage math, reconstitution, COA checks and protocol context for Tesamorelin.
